Pharma BD Deal Intelligence
The acquired Chennai injectables plant became a chronic quality/data-integrity liability and was permanently shut down by Pfizer in 2019 — the ~$400M asset ended in closure, not cash flow.
Full analysis, sources & comparables →The Orchid deal adds a dedicated cephalosporin/penicillin/carbapenem complex and an Indian R&D base, positioning Hospira as a global low-cost injectables…
Post-deal, Orchid used the Hospira proceeds to pay down debt and refocus on APIs and non-beta-lactam formulations, validating the divestiture's strategic logic.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Hospira acquired Orchid Chemicals & Pharmaceuticals' generic injectables (beta-lactam) business and Indian manufacturing/R&D facility for ~$400M cash (closed Mar 30, 2010). Remove the 'Source:' clause.
The acquired Chennai injectables plant became a chronic quality/data-integrity liability and was permanently shut down by Pfizer in 2019 — the ~$400M asset ended in closure, not cash flow.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals Ltd. (Generic Injectables business) (this deal) | 2009 | $400M | 22 |
| Hospira Inc. / Abbott Hospital Products Division | 2004 | — | 54 |
| Hospira Inc. / Javelin Pharmaceuticals, Inc. | 2010 | $145M | 25 |
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals (Generic Injectables Business) | 2010 | $400M | 23 |
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals Ltd. (API and R&D facilities) | 2012 | $200M | 22 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
← Browse all deals · How we score deals
More: 2009 deals · Hospira Inc. deals